TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04503889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS sham
Description: ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: taVNS sham
Description: ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
Study: NCT00859469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV infusion for 90 minutes
Study: NCT01753531

Intervention type: DEVICE
Intervention: Flu Symptoms
Study: NCT00736619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
Description: All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored.
Study: NCT02903576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection of hESC-RPE in suspension
Description: The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection hESC-RPE seeded in a substrate
Description: Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
Study: NCT02577081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT scan (CT scan)
Description: all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
Study: NCT01309919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD
Description: Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.

Intervention type: OTHER
Group type: OTHER
Intervention: Diary
Description: Subjects will keep a bleeding diary for three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diary
Description: Subjects will keep a bleeding diary for three months
Study: NCT02287454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation program: REHACOP
Description: Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
Study: NCT00729196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
Study: NCT02477904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: Dietary
Study: NCT01400269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
Description: Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
Study: NCT05023954

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Drop of blood for RNA and metabolic analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Drop of blood for RNA and metabolic analysis
Study: NCT04147481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Abdominal Nerve Block with local anesthetics
Description: surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group Abdominal Nerve Block with saline
Description: surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
Study: NCT00764855

Intervention type: PROCEDURE
Intervention: Automatic administration of propofol and opiates during routine clinical practice
Description: The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device.
Study: NCT04161872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uricemin
Description: Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03586648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Multifocal
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Multifocal
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Sphere
Description: TEST Lens Sphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Sphere
Description: TEST Lens Sphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Multifocal
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Multifocal
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Sphere
Description: CONTROL Lens Sphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Sphere
Description: CONTROL Lens Sphere
Study: NCT04480112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology based social interactions
Description: Participants will be socially interacting using any available technology with members of the research team.
Study: NCT02373475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional ventilation
Description: Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protective lung ventilation
Description: Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
Study: NCT03655210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: HL151(1Tab) once a day for 4 weeks of treatments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
Study: NCT01702350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Oral formulation of an an antibacterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Oral formulation of an an antibacterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Oral formulation of an an antibacterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Oral formulation of an an antibacterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Oral formulation of an an antibacterial
Study: NCT03952910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online pain education program
Description: Online pain education program
Study: NCT02501239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accept Yourself!

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Study: NCT03273985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Trigger point deep dry needling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Trigger point ischemic compression
Study: NCT02025309

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular monitorisation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular monitorisation
Study: NCT02886975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low protein diet plus α-keto acid
Description: 0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
Study: NCT04480112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No research related technology based social interactions
Description: No technology based social interactions with the research team.
Study: NCT01880424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching Placebo Capsules, Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide 290 ug Capsules, Oral, once daily
Study: NCT03328754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerscope placed bilaterally for class II correction
Description: Powerscope placed bilaterally for class II correction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2 Forsus
Description: Forsus placed bilaterally for class II correction
Study: NCT02267395

Intervention type: OTHER
Intervention: (1) cranio-cervical flexion test;
Description: Test to determine level of strength for Deep Neck Flexor muscles

Intervention type: OTHER
Intervention: (1) cranio-cervical flexion test;
Description: Test to determine level of strength for Deep Neck Flexor muscles

Intervention type: OTHER
Intervention: (2) scapular dyskinesis test
Description: Test to determine scapular control

Intervention type: OTHER
Intervention: (2) scapular dyskinesis test
Description: Test to determine scapular control

Intervention type: OTHER
Intervention: (3) deep neck flexor endurance test.
Description: Test do determine endurance for the deep neck flexor muscle group.

Intervention type: OTHER
Intervention: (3) deep neck flexor endurance test.
Description: Test do determine endurance for the deep neck flexor muscle group.
Study: NCT03616548

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endoscopic surveillance
Description: Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
Study: NCT01987648

Intervention type: PROCEDURE
Intervention: Elective Craniotomy Patients
Description: Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
Study: NCT03754296

Intervention type: DEVICE
Intervention: CATCHVIEW
Description: Revascularization device
Study: NCT01464203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT coronary angiography
Description: CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
Study: NCT02790853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo brush biopsy and incisional biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo PS2.1/PS3 imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy
Description: Undergo HRME imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: Applied on mucosa
Study: NCT01187758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshops and focus group meetings
Description: Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
Study: NCT01983293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QLV based implant strategy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care implant strategy
Study: NCT03581305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDOPA
Description: High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-DASB
Description: High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
Study: NCT01747772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Sonoelastography
Description: Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
Study: NCT03147248

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (90 mg) by single SC injection every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (180 mg) by double SC 90 mg injections every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Study: NCT02062632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin Hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04764058

Intervention type: DRUG
Group type: OTHER
Intervention: Tienam 500
Description: Imipenem and cilastatin sodium

Intervention type: DRUG
Group type: OTHER
Intervention: Tienam 500
Description: Imipenem and cilastatin sodium

Intervention type: DEVICE
Group type: OTHER
Intervention: Infusion
Description: Health caregivers give the drug to the patients and monitoring the infusion rate

Intervention type: DEVICE
Group type: OTHER
Intervention: Infusion
Description: Health caregivers give the drug to the patients and monitoring the infusion rate
Study: NCT05197335

Intervention type: DEVICE
Intervention: Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws
Description: The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
Study: NCT03418454

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal mucosa samples for Extraction of BACTERIAL DNA
Description: Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome).

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal mucosa samples for Extraction of BACTERIAL DNA
Description: Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome).

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal mucosa samples for Extraction of BACTERIAL DNA
Description: Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome).

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal mucosa samples for Extraction of BACTERIAL DNA
Description: Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome).

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal mucosa samples for Extraction of BACTERIAL DNA
Description: Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome).
Study: NCT03775239

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness in Sex Therapy and Intimate Relationships (MSIR)
Description: Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual
Description: The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual
Description: The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy.
Study: NCT01229098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
Description: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
Study: NCT03094026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumosity
Description: Computer-based online cognitive training program using the Lumosity cognitive training program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumosity (waitlist control)
Description: Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
Study: NCT02151279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan as wine fining agent
Description: The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control